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A new hepatitis B virus variant selected during lamivudine treatment was detected, in
which the methionine (rtM204) in the so-called YMDD motif in the C domain of the
catalytic site of the polymerase gene was replaced by a serine (rtM204S). This change
simultaneously resulted in a tyrosine-195 into valine variant (sY195V) in the surface
protein HBsAg. The detection of this YSDD variant was initially observed, after an
increase of HBV DNA levels, by sequencing of amplification products from day 586. A
specific RFLP assay was developed that could identify 10% of YSDD-containing variants
in the virus pool, which enabled detection of this new variant virus at day 506. However,
by cloning several PCR products and sequencing individual recombinant clones, the
mutation was first identified at day 477, before a significant increase of HBV DNA was
observed in serum. The mutation was followed by a leucine to methionine change at
position 180 (rtL180M). The consequences of this mutation for disease management and
diagnostic strategies are discussed.
Introduction
Potent inhibitors of hepatitis B virus (HBV) replication
such as lamivudine, (-)2’,3’-dideoxy-3’-thiacytidine,
have recently become available. In several clinical
trials, lamivudine therapy resulted in a rapid decline of
serum HBV DNA levels in a majority of patients [1–
5]. However, as with other antiviral agents, HBV
variants resistant to the drug may emerge during
prolonged treatment [2, 4, 6–10] and, after cessation
of therapy, HBV DNA serum levels may return to pre-
treatment values. Even enhanced HBV replication,
resulting in a hepatitis flare, has been described [11].
Resistance to lamivudine occurs in up to 39% of
patients with chronic hepatitis after 1 year of therapy.
Resistance is indicated by an increase of HBV DNA
levels often followed by ALT elevation. It has been
attributed solely to variations in the so-called YMDD
region of the polymerase gene, in which the methionine
(rtM204) is replaced by either valine (rtV204) or
isoleucine (rtI204). The replacement by valine is
accompanied by a change of leucine (rtL180) to
methionine (rtM180) [8, 10].
This paper describes the identification of a new variant
in the YMDD region and discusses the possible
intermediates involved in its emergence. Implications
for the use of different strategies to monitor the
emergence of variant viruses are discussed. The
consensus rt domain numbering system as proposed
by Stuyver et al. [12] has been used to describe the
variants. This numbering system is genotype indepen-
dent and allows a more standardised way of describing
the antiviral-related changes.
Materials and methods
Patient and clinical samples
A patient of Vietnamese origin with chronic HBV
infection was treated with lamivudine 150 mg daily for
a period of 756 days. The follow-up period was up to
126 days after the end of treatment (day 882). Between
days 113 and 125, interferon was added (7 days with
10 MU and 5 days with 5 MU) but this was withdrawn
because of side-effects. All serum samples were stored
frozen at 208C until use.
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Measurement of HBV DNA in serum
Where necessary, serum samples were diluted in known
HBV DNA-negative serum. For the accurate measure-
ment of HBV DNA in serum, the Digene Hybrid
Capture plate assay and an in-house TaqMan assay
were used [13, 14]. The Digene assay enabled the
accurate determination of HBV DNA above
200 000 copies=ml, while the TaqMan-based assay
enabled accurate determination down to 373 copies=ml
without a sample concentration step. Differences in
HBV DNA load greater than three-fold were consid-
ered significant. All data were related to the EUROHEP
HBV DNA standards [15].
Sequence analysis
A selected genomic region of the polymerase gene was
amplified and sequenced with primers described
previously [16]; 2-l amplicons were amplified with
the DYEnamicTM terminator cycle sequencing kit
according to the manufacturer’s protocol (Amersham
Pharmacia, Roosendaal, The Netherlands). The PCR
products were precipitated with 3 M NaAc, pH 5.3,
ethanol 96% and centrifuged for 1 h at 2500 g at room
temperature. Subsequently the pellets were washed with
ethanol 70% and resuspended in 4 l of loading dye.
The products were analysed on the ABI 373 sequencer
(Applied Biosystems, Nieuwerkerk a/d IJssel). Selected
PCR products were cloned into the pCRII TA vector
(InVitrogen, Leek, The Netherlands). After selection of
clones, a PCR reaction with the primers as above was
performed directly on the recombinant colonies.
RFLP analysis of YSDD
To develop a more specific screening assay for the
YSDD variant, a restriction fragment length poly-
morphism (RFLP) assay was developed. This detects
nucleotide changes in the HBV polymerase with the
restriction endonuclease SfcI (CT.PuPyAG; New
England Biolabs, Beverly, MA, USA). The specific
endonuclease site was introduced with a modified
primer in the PCR (sense cac.tgt.ytg.gct.agc.tat; anti-
sense gtt.yaa.atg.tat.acc.caa.ag), generating an amplifi-
cation product of 120 bp. In case of a YSDD variant, a
fragment of 105 bp was detected by Metaphor agarose
3% gel electrophoresis with Gelstar 0.01% as inter-
calating dye.
Results
Clinical monitoring
Routine monitoring of patients receiving lamivudine
was performed by HBV DNA quantitative assays and
ALT measurements. Increased serum HBV DNA levels
are indicative of resistance to lamivudine. In Fig. 1, the
HBV DNA measurements and the ALT levels are
documented from a chronically infected patient receiv-
ing lamivudine 150 mg daily for a period of 756 days.
ALT values were within the normal range during and
after therapy, except when interferon was added. The
maximal antiviral effect of lamivudine was a 5.11 log10
HBV DNA decrease down to 10 000 copies=ml at day
244. HBV DNA levels remained at 4–4.77 log10
between days 127 and 378. A 0.5 log10 increase of
HBV DNA was observed at day 506 compared with
day 441, after which levels increased to 8.31 log10 at
day 756. After the end of therapy, HBV DNA levels
rose to 8.85 log10, similar to the pre-treatment value.
Sequence analysis
Sequencing of PCR products at days 586 and 623
identified a change of rtM204S, together with an
rtL180M change. At day 506, only YMDD wild-type
sequences were found but day 532 both rtM204 and
rtS204 were detected simultaneously. The methionine
to serine change was the result of a two nucleotide
change of ATG into AGT, thereby also introducing a
tryptophan to valine substitution at position 195 of the
HBsAg (sY195V, TGG changed to GTG). The virus
was typed as HBV genotype B (ayw1 serotype
according to [17]).
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Fig. 1. HBV DNA and ALT levels in a patient with a confirmed rtS204 variant in the polymerase gene (C domain). The patient
received lamivudine 150 mg/day for 756 days. Days on which the rtS204 sequence was confirmed by analysis of PCR product or
RFLP analysis are indicated by arrows.
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As sequencing of PCR products by itself is not able to
detect minor variants, amplification products generated
between days 477 and 532 were cloned and up to 40
independent clones per time point were sequenced. At
day 477, 95% of the clones sequenced contained wild-
type rtM204 sequences, 2.5% of the clones contained
only the rtS204 change, and 2.5% of the clones
contained both rtS204 and rtM180. At day 506, 72.4%
of the clones contained wild-type rtM204 sequences,
24.1% contained the rtM180 and rtS204 changes and
3.4% contained only the rtS204 change. At day 532,
these percentages were 72% for wild-type rtM204
sequences, 20% for both rtM180 and rtS204 changes,
and 8% for only the rtS204 change. After day 532,
100% variant sequences rtM180 and rtS204 were
detected.
RFLP analysis
To enable easy and early detection of YSDD variants, a
specific RFLP assay was developed with the restriction
endonuclease SfcI and a modified amplification primer.
The RFLP assay had a detection limit down to 1000
copies/ml, with the EUROHEP HBV DNA standard as
reference, and enabled the detection of 10% YSDD-
containing variant virus in a total HBV population
(data not shown).
RFLP analysis of samples from selected dates during
and after treatment was performed (Fig. 2). The first
indication for the presence of a YSDD variant was a
minor band representative of this variant obtained at
day 506. At day 596, the minor HBV population
contained wild-type sequences. At day 623 only YSDD
variant sequences could be detected until the end of
treatment (day 756). Wild-type sequences were already
detected 13 days after the end of treatment. Surpris-
ingly, until the last sample analysed at day 882, both
YSDD and YMDD sequences were detected in equal
amounts. No return to wild-type sequences only was
seen.
Discussion
A new HBV variant isolated from a patient with a
chronic hepatitis B virus infection has been described.
In this variant, which was genotypically characterised
during prolonged treatment with lamivudine, the
rtM204 of the YMDD domain in the polymerase gene
was changed into rtS204. The data on the rtS204
variant confirm the presence of this variant during
lamivudine treatment in the patient, but do not prove an
actual reduced drug susceptibility. The two previously
described mutations in this domain are known as
rtM204I and rtM204V, both of which result in reduced
replication of HBV [18].
We and others have shown that mutations related to
lamivudine arise during prolonged treatment, both in
transplant patients and in other chronically infected
HBV patients [4, 7, 10, 19, 20]. However, the incidence
and patterns with which they occur may be different in
the populations studied. It has been demonstrated
clearly that the major mutation responsible for
resistance is located in the C domain of the catalytic
YMDD site of the polymerase gene. Furthermore, a
second mutation rtL180M in the B domain of the
polymerase is often linked to the particular rtM204V
change. However, this correlation has also been
described recently in a limited number of patients with
the rtI204 variant [6, 7].
There are accumulating data from molecular modelling
and biochemical characterisation of variants that give
more detailed insight into the mechanism of resistance
of HBV and HIV-1 to lamivudine [21–23]. Steric
hindrance between the side chains of the -branched
amino acids valine, isoleucine and threonine in the
YMDD motif with the oxathiolane ring of lamivudine
most likely accounts for the phenotypic resistance of
both viruses [22, 23]. This model may be a simplifica-
tion, as in-vitro studies have shown that, for example,
YADD variants of HIV-1 and Moloney murine
leukemia virus are also resistant to lamivudine [21].
These authors suggest that other structural changes of
the polymerase active site due to the mutation or the
repositioning of the complex between the polymerase,
the nucleic acid and the dNTP binding site eventually
lead to steric hindrance. The described rtS204 variant
of HBV would most likely cause changes in this
replication complex according to this model.
Fig. 2. RFLP analysis for the rapid detection of the rtS204 variant in the polymerase gene of HBV. PCR primers were designed to
amplify a region of 120 bp. After digestion with the restriction endonuclease SfcI, a 15-bp fragment is removed from YSDD
variants, leaving a 105-bp fragment. M, marker line (no signal).
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The YADD and YSDD mutants of HIV-1 are replica-
tion competent in vitro, but have not been observed in
vivo in HIV-1-infected individuals [24]. Proviruses with
reverse transcriptase containing these mutations were
less infectious than wild-type virus. All reported
variants related to lamivudine resistance selected in
vivo so far have been caused by a single nucleotide
change, whereas two mutations are required to convert
the methionine codon into an alanine or serine codon.
The change of methionine into serine in the HBV-
infected patient in the present study is due to the
change of ATG into AGT. As a working hypothesis it
was assumed that a YIDD intermediate with the coding
sequence ATT should precede the occurrence of the
YSDD variant. However, despite screening of a large
number of individual recombinant clones, this inter-
mediate was not found.
The present study also addressed the time course of
changeover from wild-type into variant sequence, as
well as the events that occurred after the end of
therapy. It was expected that after the end of therapy,
wild-type sequences would be detected within a month
without the detection of variant sequences. However,
wild-type as well as variant viruses were detected in
almost equal frequencies from day 13 onward until the
last sample analysed 3 months later. A plausible
explanation for this observation is that the replicative
intermediate, known as covalently closed circular DNA
(cccDNA), of HBV containing the variant sequences
has established itself in the liver. As this cccDNA is
not inhibited by lamivudine, the variant virus may have
infected a large proportion of hepatocytes, as indicated
by the high viral load of variant virus present at the
end of treatment.
From a diagnostic point of view, the question arises as
to how these variants can be predicted or identified as
easily and quickly as possible. Assuming that the
variant strains replicate less efficiently than wild-type
virus, but better than the maximally suppressed virus
population, accurate and well standardised viral load
measurements should be indicative. Use of both a
commercially available assay as well as an in-house
assay demonstrated this phenomenon. Furthermore,
easy-to-use methods to identify viral strains have been
proposed, such as the RFLP method and the InnoLipa
HBV reverse hybridisation assay [25, 26]. Both meth-
ods seem to be sensitive, but can be used only for the
identification of known variants, which is the crucial
problem. We have been sequencing routinely variant
populations even though this lacks sensitivity. However,
it is the only method currently available which enables
identification of new mutations that could be related to
resistance, in combination with accurate viral DNA
measurements.
In conclusion, the present study has shown for the first
time the detection of a new variant of HBV selected
under lamivudine treatment. This YSDD variant was
also linked with the rtL180M substitution. The popu-
lation of viruses present in circulation after the end
of therapy contained both wild-type and variant
sequences. Furthermore, these findings suggest that
the use of different techniques to screen for these
variants should always include sequence analysis. It is
possible that more variants will be found to arise
during treatment with lamivudine.
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